Please assess the completion status of the following clinical trial:

Trial Title: Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) class 1 - 2, between the ages of 28 days and 65 years inclusive, and between the ages of 2 and 65 years inclusive for Germany and between the ages of 6 and 65 years inclusive for Finland~* Scheduled for general anesthesia with an anticipated duration of anesthesia of at least 60 minutes, without further need for muscle relaxation other than one single dose of 0.6 mg/kg rocuronium~* Scheduled for surgical procedures in the supine position~* Participants who, and/or whose parent(s) or legal guardian(s) have given written informed consent \[or appropriate assent, if applicable\]~Exclusion Criteria:~* Known or suspected neuromuscular disorders impairing neuromuscular blockade (NMB) and/or significant renal dysfunction, in Germany creatinine and blood urea nitrogen outside local reference ranges~* Known or suspected to have a (family) history of malignant hyperthermia~* Known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia~* Use of medication expected to interfere with the rocuronium given in this trial, based on the dose and the time of administration~* Pregnancy~* Childbearing potential not using any of the following methods of birth control: condom or diaphragm with spermicide, vasectomized partner (\>6 months), intrauterine device (IUD), abstinence~* Breast-feeding~* Prior participation in any study with Org 25969 (sugammadex)~* Participation in another clinical trial, not pre-approved by NV Organon, within 30 days of entering into study 19.4.306 (MK-8616-034, P05961)

- Gender: ALL
- Minimum Age: 28 Days
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sugammadex 0.5 mg/kg (Type: EXPERIMENTAL): Participants are to receive an intravenous (IV) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex is to be given.
- Sugammadex 1 mg/kg (Type: EXPERIMENTAL): Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex is to be given.
- Sugammadex 2 mg/kg (Type: EXPERIMENTAL): Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex is to be given.
- Sugammadex 4 mg/kg (Type: EXPERIMENTAL): Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex is to be given.
- Placebo (Type: PLACEBO_COMPARATOR): Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single 3-mL bolus dose of placebo (sodium chloride 0.9% solution) is to be given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete